

SYMATESE

THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION,
AND ITS ADMINISTRATION SYSTEMS FOR THE BENEFIT OF DOCTORS AND PATIENTS.

Press Release

Bornel, near Paris, France, August 4, 2026

SYMATESE EXPANDS STRATEGIC PARTNERSHIP WITH
EVOLUS TO COMMERCIALIZE ESTYME® IN CANADA,
AUSTRALIA, AND NEW ZEALAND.

Symatese Group, a leading expert in hyaluronic acid, today announced it has expanded its partnership with Evolus through an amendment to the companies' existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize its ESTYME® (pronounced "esteem") collection of injectable hyaluronic acid (HA) gels under the brand name in Canada, Australia, and New Zealand.

The agreement further reinforces Symatese' long-standing partnership with Evolus and extend ESTYME® footprint internationally. Upon regulatory approval, Evolus will commercialize the complete product ESTYME® collection across Canada, Australia, and New Zealand, complementing its existing Nuceiva® neurotoxin franchise and allowing Evolus to market our Symatese injectable HA gel portfolio in every market where it currently markets its botulinum toxin. The dermal filler markets across these 3 countries contribute a total addressable market of approximately \$200 million annually.

"We are proud to partner with Evolus and expand ESTYME® into those key markets— building on the successful launches of Evolysse® in the U.S. in April 2025 and ESTYME® recently in Europe and France. With decades of experience in biomaterial science in aesthetics and in therapeutical domains, Symatese has a strong legacy of developing innovative aesthetic products that meet the evolving needs of practitioners and their patients," said Jean-Paul Gérardin, Chief Executive Officer of Symatese. He explained: this gave birth thanks to the Symatese scientific team to the ESTYME® collection consisting of a full range of injectable HA gels utilizing Symatese's innovative COLD-X® TECHNOLOGY that helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results.

Under the terms of the agreement, Symatese will remain responsible for product development, manufacturing, clinical support, and regulatory activities required to obtain and maintain marketing approvals within the licensed territories. Evolus will make an upfront payment to Symatese along with additional payments tied to the achievement of specified regulatory approval milestones. Evolus will also purchase product from Symatese at an agreed transfer price and pay a mid-single digit royalty based on net sales. The agreement is expected to be accretive to Evolus' international gross margins while leveraging the company's existing commercial organization, digital platform, and distribution infrastructure across these markets. Commercialization of ESTYME® in Canada, Australia, and New Zealand is expected to begin in 2028, subject to applicable regulatory approvals and review processes.

SYMATEse

THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION,
AND ITS ADMINISTRATION SYSTEMS FOR THE BENEFIT OF DOCTORS AND PATIENTS.

About SYMATESE

With almost 30 years of existence, Symatase has established itself as a leading expert in the science of tissue regeneration. Thanks to cutting-edge research and its technological platform integrating collagen, hyaluronic acid, silicones and thermoplastics, the company develops innovative medical solutions that transform patients' lives and revolutionize practices in some fifteen medical specialties. Drawing on its expertise in therapeutic areas, we have made significant advances in aesthetic medicine. Agreements have been reached with renowned partners to access global coverage, in particular with Evolus Inc., thanks to the collaborations established in May and December 2023 respectively for the USA and Europe, while Evolus' neurotoxin, Nuceiva[®] and Estyme[®] dermal fillers are commercialized in France by a subsidiary of Symatase. These agreements are part of Symatase' Transform Plan 2025-2029, marked in 2024 by the launch on the American market of Lacrifill[®] for the treatment of dry eye with our partner Nordic Pharma, followed by the commercialization in Brazil, by our Brazilian subsidiary, of the Estyme[®] Matrix range of breast implants, based on Pryme[®] Technology by Symatase. With its continued commitment to research and development, Symatase is accelerating its global rollout in 2026 already initiated in 2024 and is well positioned to continue shaping the future of regenerative and aesthetic medicine. Visit us at <http://www.symatase.com>, and follow us on [LinkedIn](#)

Evolysse[®] is a registered trademarks of Evolus, Inc.

Estyme[®] and Cold-X[®] are registered trademarks respectively by Symatase Aesthetics S.A.S. and Symatase S.A.S

Symatase Contacts:

Symatase - Laurent BRONES - +33 6 14 31 13 57